Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:55:45.692Z.
Calculation as of: 2026-10-06T21:55:45.692Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 92e82853ec35d591c91e1857ba5f245e9338475f566e1ab86be3b7c1b83139db
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Artiva Biotherapeutics, Inc.
Market Cap
$355.43M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$355.36M
EV/EBIT Ratio
14.50x
TTM Avg
15.92x
3Y Avg
18.69x
5Y Avg
21.92x
Market Cap
$353.88M
EV/EBIT Ratio
N/A
TTM Avg
45.54x
3Y Avg
33.14x
5Y Avg
24.49x
Market Cap
$359.53M
EV/EBIT Ratio
N/A
TTM Avg
55.83x
3Y Avg
55.83x
5Y Avg
55.83x
Market Cap
$349.70M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $355.43M | N/A | N/A | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 14.50x | 15.92x | 18.69x | 21.92x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A | 45.54x | 33.14x | 24.49x |
| Embecta Corp. (EMBC)vs › | $353.00M | 6.48x | 5.53x | 9.02x | 8.48x |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 55.83x | 55.83x | 55.83x |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
